eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
1/2015
vol. 19
 
Share:
Share:
abstract:
Original paper

The use of Yttrium-90 Ibritumomab Tiuxetan (90Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation

Wojciech Jurczak
,
Elżbieta Kisiel
,
Joanna Sawczuk-Chabin
,
Piotr Centkowski
,
Wanda Knopińska-Posłuszny
,
Omeir Khan

Contemp Oncol (Pozn) 2015; 19 (1): 43–47
Online publish date: 2015/03/26
View full text Get citation
 
PlumX metrics:
Aim of the study: To evaluate the efficacy and safety of Yttrium-90 Ibritumomab Tiuxetan (90Y-IT) as a consolidation therapy in the management of DLBCL.

Material and methods: Patients with primary refractory or high-risk DLBCL (n = 18), ineligible for autologous stem-cell transplantation, were included in a retrospective study performed at three centers by the Polish Lymphoma Research Group (PLRG). All patients (mean age 61, range 35–82) either didn’t achieve a complete response or didn’t complete the scheduled therapy due to its complications. Response rates (CR, PR, SD, PD) according to Cheson criteria, overall survival (OS), progression-free survival (PFS) and adverse effects of radioimmunotherapy were analyzed.

Results: Consolidation radioimmunotherapy increased the CR rate from 38% (n = 7) to 82% (n = 15). One pa­tient remained in PR, one patient remained in SD, while one patient remained in PD. During a median follow-up of five years, 11 patients (62%) were alive with no recurrence, 4 patients (22%) were alive with relapse while 3 patients (16%) died. There was no statistically significant difference in PFS between those in CR and those in PR before 90Y-IT.

Conclusions: Radioimmunotherapy is an effective consolidation therapy for high risk/refractory DLBCL patients and worthy of further investigation in prospective trials.
keywords:

diffuse large B-cell lymphoma, radioimmunotherapy, Yttrium-90 Ibritumomab Tiuxetan, consolidation

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.